Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ipilimumab biosimilar - Innovent Biologics

Next Previous
Drug Profile

Ipilimumab biosimilar - Innovent Biologics

Alternative Names: Anti-CTLA-4 antibody - Innovent Biologics; IBI-310; Ipilimumab N01

Latest Information Update: 06 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovent Biologics
  • Developer Innovent Biologics; Peking University
  • Class Antineoplastics; Antiretrovirals; Immunotherapies; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Colorectal cancer
  • Phase III Acral lentiginous melanoma; Liver cancer
  • Phase II Cervical cancer; Gastric cancer; Neuroendocrine tumours
  • Phase I/II Biliary cancer; Nasopharyngeal cancer
  • No development reported Non-small cell lung cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 01 Apr 2026 Tianjin Medical University Cancer Institute and Hospital plans a phase II trial for Colorectal cancer (Combination therapy, Metastatic, Late-stage disease, Inoperable/Unresectable) (IV) in March 2026 (NCT07506109)
  • 24 Mar 2026 Innovent Biologics plans a phase II/III for Liver cancer (first-line therapy, Late-stage diseases, Combination therapy, In operable/Unresectable) in China (IV), in March 2026 (NCT07490262)
  • 18 Mar 2026 Sun Yat-sen University in collaboration with Innovent Biologics plans the phase II ACTION-001 trial for Liver cancer (Combination therapy, Neoadjuvant therapy, First-line therapy) (IV) (NCT07487662)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top